¼¼°èÀÇ ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀå
Clinical Trial Patient Recruitment Services
»óǰÄÚµå : 1774719
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 490 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀåÀº 2030³â±îÁö 15¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 9¾ï 6,920¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 7.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 15¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠȯÀÚ ¸ðÁý ¹× µî·Ï ¼­ºñ½º´Â CAGR 8.7%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 7,790¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ȯÀÚ À¯Áö ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 6,410¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀåÀº 2024³â¿¡ 2¾ï 6,410¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 11.6%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 3¾ï 1,370¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.5%¿Í 7.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ȯÀÚ ¸ðÁýÀÌ ÀÓ»ó½ÃÇè¿¡¼­ °¡Àå Å« ¹®Á¦ÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ȯÀÚ ¸ðÁýÀº ¿©ÀüÈ÷ ÀÓ»ó½ÃÇèÀÇ °¡Àå Å« º´¸ñÇö»ó Áß ÇϳªÀ̸ç, 80% ÀÌ»óÀÇ ÀÓ»ó½ÃÇèÀÌ µî·Ï ¹®Á¦·Î ÀÎÇØ Áö¿¬À» °æÇèÇϰí ÀÖ½À´Ï´Ù. º¹ÀâÇÑ Âü¿© ÀÚ°Ý ±âÁØ, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, Àӻ󿬱¸¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ³·Àº ÀÎ½Ä µîÀÌ È¯ÀÚ ¸ðÁýÀÇ ¾î·Á¿òÀÇ ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó½ÃÇè ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º °ÝÂ÷ ¹× µî·Ï ȯÀÚ±ºÀÇ ´Ù¾ç¼º ºÎÁ·Àº ¸ðÁý Ȱµ¿À» ´õ¿í ¾î·Æ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. Á¦¾à»ç¿Í CRO´Â ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ È¯ÀÚ ¸ðÁý ¼­ºñ½º¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, µðÁöÅÐ ¾Æ¿ô¸®Ä¡, ¼Ò¼È ¹Ìµð¾î Ä·ÆäÀÎ, AI¸¦ Ȱ¿ëÇÑ È¯ÀÚ ¸ÅĪ ¾Ë°í¸®Áò µîÀ» Ȱ¿ëÇÏ¿© µî·Ï È¿À²À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Áö¿ø ´Üü¿Í Ä¿¹Â´ÏƼ Âü¿© ÀÌ´Ï¼ÅÆ¼ºê´Â ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚ¿Í ÀáÀçÀû Âü¿©ÀÚ °£ÀÇ °£±ØÀ» Á¼È÷´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á ¹× Èñ±ÍÁúȯ ÀÓ»ó½ÃÇèÀÌ È®»êµÊ¿¡ µû¶ó ƯÁ¤ À¯ÀüÀû ¹× Àα¸Åë°èÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Ÿ°ÙÆÃµÈ ¸ðÁý Àü·«ÀÇ Çʿ伺ÀÌ Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù.

¾î¶² Çõ½ÅÀÌ È¯ÀÚ ¸ðÁý Àü·«À» °³¼±Çϰí Àִ°¡?

¸î °¡Áö Çõ½ÅÀûÀÎ Àü·«Àº ȯÀÚ ¸ðÁý¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ µî·ÏÀ» º¸´Ù È¿À²ÀûÀÌ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·Ï(EHR), À¯ÀüÀÚ µ¥ÀÌÅÍ, °Ç°­ÀÇ »çȸÀû °áÁ¤ ¿äÀÎÀ» ±â¹ÝÀ¸·Î Àû°Ý ȯÀÚ¸¦ ½Äº°Çϱâ À§ÇØ AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®ÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. µðÁöÅÐ ¸¶ÄÉÆÃ Ä·ÆäÀΰú ȯÀÚ Âü¿© Ç÷§ÆûÀº Çൿ ÀλçÀÌÆ®¸¦ Ȱ¿ëÇÏ¿© ¾Æ¿ô¸®Ä¡¸¦ °³ÀÎÈ­Çϰí Âü¿©À²À» ³ôÀ̱â À§ÇØ Çൿ ÀλçÀÌÆ®¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í °¡»ó ÀÓ»ó½ÃÇè ¸ðµ¨Àº Áö¸®Àû À庮À» ³·Ãç ¿ø°ÝÁö ȯÀڵ鵵 ´ë±Ô¸ð À̵¿ ¾øÀ̵µ ÀÓ»ó½ÃÇè¿¡ µî·ÏÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºí·ÏüÀÎ ±â¼úÀº ȯÀÚ ¸ðÁý Ç÷§ÆûÀÇ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾ÈÀ» °­È­ÇÏ¿© Âü¿©ÀÚÀÇ ½Å·Ú¿Í ÄÄÇöóÀ̾𽺸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀº ±âÁ¸ ÀÓ»ó ȯ°æ ¿ÜÀÇ ½ÇÁ¦ µ¥ÀÌÅÍ ¼öÁýÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ȯÀÚ ¸ðÁý Ç®À» ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚ ¸ðÁýÀÇ ¿À·£ ³­Á¦¸¦ ÇØ°áÇϰí, ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» Çâ»ó½Ã۸ç, ÀǾàǰ °³¹ß ±â°£À» ´ÜÃàÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ä¿ë¿¡¼­ ȯÀÚ Áö¿ø ´ÜüÀÇ ¿ªÇÒÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

ȯÀÚ Áö¿ø ´Üü´Â ÀÎÁöµµ¸¦ ³ôÀ̰í, Áö¿ª»çȸ¸¦ ±³À°Çϰí, Âü°¡ÀÚ¸¦ Áö¿øÇÔÀ¸·Î½á ÀÓ»ó½ÃÇè ¸ðÁý¿¡ ÀÖ¾î Á¡Á¡ ´õ ¿µÇâ·Â ÀÖ´Â ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ´Üü´Â ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚ¿Í Çù·ÂÇÏ¿© ȯÀÚ Áß½ÉÁÖÀÇ, ¹®È­Àû ¹Î°¨¼º, Æ÷¿ë¼ºÀ» ¿ì¼±½ÃÇÏ´Â ¸ðÁý Àü·«À» °øµ¿À¸·Î °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ËÈ£´Üü´Â ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚ¿Í ¼Ò¿ÜµÈ ȯÀÚ Áý´Ü°úÀÇ °ü°è¸¦ °­È­ÇÏ¿© ÀÓ»ó½ÃÇè Âü¿©ÀÇ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ´Üü´Â µðÁöÅÐ Çコ Ç÷§ÆûÀ» Ȱ¿ëÇÏ¿© ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ ½Ç½Ã°£À¸·Î Á¦°øÇÔÀ¸·Î½á ȯÀÚ¿ÍÀÇ Á÷Á¢ÀûÀÎ ¼ÒÅëÀ» ÃËÁøÇϰí Å»¶ô·üÀ» ³·Ãß±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ½Å·Ú¿Í Åõ¸í¼ºÀ» ÁõÁø½ÃÅ´À¸·Î½á ȯÀÚ Áö¿ø ´Üü´Â ¿¬±¸ÀÚ¿Í Âü¿©ÀÚ¸¦ ¿¬°áÇØ ÀÓ»ó½ÃÇèÀ» º¸´Ù Ä£±ÙÇÏ°í ´Ù¾çÇÑ ¹æ½ÄÀ¸·Î Á¢±ÙÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó½ÃÇè ÇÁ·ÎÅäÄÝÀÇ º¹À⼺ Áõ°¡, ȯÀÚ µî·ÏÀÇ ½Å¼Ó¼º ¿ä±¸, ¸ðÁý Àü·«¿¡ µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)°ú ¿ø°Ý ȯÀÚ Âü¿© Ç÷§ÆûÀÇ È®´ë·Î ÀÎÇØ ¸ðÁýÀÌ ´õ¿í È¿À²ÀûÀ̰í È®À强ÀÌ ³ô¾ÆÁ³½À´Ï´Ù. Àӻ󿬱¸¿¡¼­ ´Ù¾ç¼º¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ºÆù¼­µéÀÌ Ä¿¹Â´ÏƼ Áß½ÉÀÇ ¸ðÁý Àü·«°ú µðÁöÅÐ ¾Æ¿ô¸®Ä¡ Ä·ÆäÀο¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹Àº ¸®¾ó¿ùµå Áõ°Å(RWE)¿Í ȯÀÚ º¸°í °á°úÀÇ Á߿伺À» °­Á¶Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó Àß ¼³°èµÈ ¸ðÁý ¼­ºñ½ºÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ȯÀÚ ¸ÅĪ ¹× Àû°Ý¼º ½ºÅ©¸®´×À» À§ÇØ AI¿Í ¸Ó½Å·¯´×À» µµÀÔÇÏ¸é µî·Ï ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­ÇÏ°í ºñ¿ëÀ» Àý°¨ÇÏ¸ç ½ÃÇè Áö¿¬À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÎÀç ¼Ò°³ ȸ»ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× ±â¼ú ±â¾÷ °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº ȯÀÚ ¸ðÁý ¼­ºñ½ºÀÇ È¿À²¼º°ú È¿°ú¸¦ ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

ºÎ¹®

¼­ºñ½º À¯Çü(ȯÀÚ ¸ðÁý ¹× µî·Ï ¼­ºñ½º, ȯÀÚ À¯Áö ¼­ºñ½º, ±âŸ ¼­ºñ½º);´Ü°è(´Ü°è I, ´Ü°è II, ´Ü°è III, ´Ü°è IV);Ä¡·á ¿µ¿ª(È£Èí±âÁúȯ, ÅëÁõ ¹× ¸¶Ãë, Á¾¾ç, ÁßÃ߽Űæ°è, ¼øÈ¯±â, ³»ºÐºñ, Ç×°¨¿°Áõ, ±âŸ Ä¡·á ¿µ¿ª);¿¬·ÉÃþ(17¼¼±îÁö, 18-64¼¼, 64¼¼ ÀÌ»ó)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Trial Patient Recruitment Services Market to Reach US$1.5 Billion by 2030

The global market for Clinical Trial Patient Recruitment Services estimated at US$969.2 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Patient Recruitment & Registry Services, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$677.9 Million by the end of the analysis period. Growth in the Patient Retention Services segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$264.1 Million While China is Forecast to Grow at 11.6% CAGR

The Clinical Trial Patient Recruitment Services market in the U.S. is estimated at US$264.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$313.7 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Clinical Trial Patient Recruitment Services Market - Key Trends & Drivers Summarized

Why Is Patient Recruitment a Persistent Challenge in Clinical Trials?

Patient recruitment remains one of the most significant bottlenecks in clinical trials, with over 80% of trials experiencing delays due to enrollment challenges. The increasing complexity of eligibility criteria, stringent regulatory requirements, and low patient awareness about clinical research contribute to recruitment difficulties. Additionally, disparities in access to trial sites and lack of diversity in enrolled populations further hinder recruitment efforts. Pharmaceutical companies and CROs are investing heavily in patient recruitment services to address these challenges, leveraging digital outreach, social media campaigns, and AI-driven patient matching algorithms to improve enrollment efficiency. Moreover, patient advocacy groups and community engagement initiatives are playing a crucial role in bridging the gap between trial sponsors and potential participants. As precision medicine and rare disease trials become more prevalent, the need for targeted recruitment strategies tailored to specific genetic and demographic profiles is becoming increasingly essential.

What Innovations Are Improving Patient Recruitment Strategies?

Several innovative strategies are revolutionizing patient recruitment, making enrollment more efficient and accessible. AI-powered predictive analytics are being used to identify eligible patients based on electronic health records (EHRs), genetic data, and social determinants of health. Digital marketing campaigns and patient engagement platforms are leveraging behavioral insights to personalize outreach and improve participation rates. Telemedicine and virtual trial models are reducing geographical barriers, allowing patients from remote locations to enroll in clinical studies without extensive travel. Additionally, blockchain technology is enhancing data privacy and security in patient recruitment platforms, increasing trust and compliance among participants. Wearable devices and remote monitoring technologies are further expanding the recruitment pool by enabling real-world data collection outside of traditional clinical settings. These advancements are collectively addressing longstanding challenges in patient recruitment, improving trial efficiency, and accelerating drug development timelines.

How Is the Role of Patient Advocacy Groups Evolving in Recruitment?

Patient advocacy groups are playing an increasingly influential role in clinical trial recruitment by raising awareness, educating communities, and providing support to participants. These organizations are partnering with trial sponsors to co-develop recruitment strategies that prioritize patient-centricity, cultural sensitivity, and inclusivity. Advocacy groups are also instrumental in connecting trial sponsors with underrepresented patient populations, helping to address disparities in trial participation. Additionally, these organizations are leveraging digital health platforms to provide real-time updates on ongoing trials, facilitating direct patient engagement and reducing dropout rates. By fostering trust and transparency, patient advocacy groups are bridging the gap between researchers and participants, making clinical trials more accessible and diverse.

What’s Driving the Growth of the Clinical Trial Patient Recruitment Services Market?

The growth in the clinical trial patient recruitment services market is driven by several factors, including the increasing complexity of trial protocols, the demand for faster enrollment, and the integration of digital health technologies in recruitment strategies. The expansion of decentralized clinical trials (DCTs) and remote patient engagement platforms is making recruitment more efficient and scalable. The growing emphasis on diversity in clinical research is encouraging sponsors to invest in community-driven recruitment strategies and digital outreach campaigns. Additionally, regulatory agencies are emphasizing the importance of real-world evidence (RWE) and patient-reported outcomes, further increasing the need for well-designed recruitment services. The adoption of AI and machine learning for patient matching and eligibility screening is accelerating enrollment processes, reducing costs, and minimizing trial delays. Strategic partnerships between recruitment firms, healthcare providers, and technology companies are further enhancing the efficiency and effectiveness of patient recruitment services.

SCOPE OF STUDY:

The report analyzes the Clinical Trial Patient Recruitment Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (Patient Recruitment and Registry Services, Patient Retention Services, Other Services); Phase (Phase I, Phase II, Phase III, Phase IV); Therapeutic Area (Respiratory Diseases, Pain and Anesthesia, Oncology, Central Nervous System, Cardiovascular, Endocrine, Anti-Infective, Other Therapeutic Areas); Age Group (Up to 17 Years, 18 - 64 years, Above 64 Years)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â